NanoCell Therapeutics
NanoCell’s NanoCAR approach uses targeted LNPs to generate CAR-T cells in vivo. Its animal proof-of-concept disclosure describes nonviral DNA delivery; this should not be classified as a transient mRNA-only platform. Clinical efficacy remains unestablished.
Corporate information
- Company entity
- NanoCell Therapeutics
- Headquarters / principal office
- Berwyn, Pennsylvania, USAOffice location disclosed on the corporate website; a sole legal or global headquarters is not inferred. ↗
- Founded
- 2021 ↗
- Ownership / capital status
- PrivateSeed extension ↗
- Official corporate reference
- https://nanocelltx.com/nanocar-overview/ ↗
- Latest financing / award identified
- 2025-06-16 · Seed extension · Amount not disclosed ↗
- LinkedIn company page
- Independent company page not verified
Disclosed equity event found in this review; not a claim that no later undisclosed event exists.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
NanoCell’s NanoCAR approach uses targeted LNPs to generate CAR-T cells in vivo. Its animal proof-of-concept disclosure describes nonviral DNA delivery; this should not be classified as a transient mRNA-only platform. Clinical efficacy remains unestablished.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Official company contact / corporate location disclosure
- NanoCell Therapeutics — supporting primary disclosure
- Official company history / founding disclosure
- Company financing announcement